GET DAILY SIGNALSTriSalus Life Sciences (TLSI): Path to $10 Target Could Deliver +251% Upside
Key Takeaways
- The central target of $10 is the arithmetic mean of five verified analyst price targets, which average $9.80 and round to $10.
- At a latest verified price near $2.85, reaching $10 implies roughly 251% upside — a very large move by any standard.
- Individual analyst targets span a wide range from $4 to $14, and all five covering analysts rate the stock a Buy.
- The strongest supports are the September 2026 FDA clearance of the TriNav Advance device and favorable 2027 Medicare reimbursement changes.
- The biggest risks are a third consecutive cut to full-year 2026 revenue guidance, slower sales-rep productivity, and ongoing cash burn.
- For more detail, explore Major News, Today's Price Move, the Forecast, and Earnings pages for TLSI.
- You can also discover data-driven trading ideas by exploring Trending AI Robots.
Analyst Price Targets and Consensus View
The central $10 target reflects five current analyst price targets that can be attributed to identifiable firms. H.C. Wainwright reiterated a Buy with a $12 target in October 2026; Lake Street reiterated Buy at $8 and Maxim Group at $14 (raised from $10) in the summer of 2026; JonesTrading reiterated Buy at $11; and Canaccord Genuity's William Plovanic lowered his target to $4 from $7 in November 2026 while keeping a Buy rating after the company's third-quarter miss and guidance reset.
Together these five targets average $9.80, rounded to the $10 figure used here. The spread is unusually wide — from $4 to $14 — reflecting sharply different assumptions about how quickly the company's expanded commercial organization can drive adoption. Analysts are uniformly constructive on the rating but divided on magnitude, with the more cautious view tied to execution risk in the sales force and the more optimistic view tied to the new TriNav Advance device and reimbursement tailwinds. This calculated mean is not an official published consensus and should be read as a range of opinion, not a guarantee. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
Following the November 2026 earnings report, TLSI shares traded near $2.85, well below the 52-week high of $7.95 and near the lower end of a 52-week range of $2.20 to $7.95. Reaching $10 would require upside of roughly 251%, a very large move that would imply a full re-rating of the company from its recent micro-cap valuation.
TriSalus reported third-quarter 2026 revenue of about $12.9 million, up 11.3% year over year, with gross margin around 86%. Yet the company cut full-year 2026 revenue guidance to $46 million to $48 million from a prior $54 million to $57 million — its third reduction of the year. Management attributed the shortfall to slower-than-expected productivity among newly hired sales representatives and a faster shift toward "super-selective" Y90 procedures in small distal vessels that the legacy TriNav device could not address.
What Could Support a Move Toward the Target
The most credible support comes from product and reimbursement catalysts rather than recent results. In September 2026 the FDA granted 510(k) clearance to TriNav Advance, which extends the PEDD platform to small distal vessels and could address the very procedural shift that hurt third-quarter growth. The company also highlights a roughly $2.5 billion U.S. addressable market across liver embolization and additional indications.
On the reimbursement side, the Centers for Medicare & Medicaid Services (CMS) finalized a calendar-year 2027 hospital outpatient payment increase for the C8004 mapping code to roughly $20,910 from about $11,874, effective January 1, 2027, alongside a new national office-based lab payment under G0577. Management points to these changes as a foundation for accelerated 2027 growth, and interim PROTECT trial data in thyroid artery embolization is expected in early 2027.
What Could Prevent the Target From Being Reached
The principal obstacle is execution. Guidance has now been reset three times, and management has deferred full-year 2027 guidance, committing only to "meaningful double-digit growth" rather than the mid-30% pace previously implied. TriNav Advance is still in limited release and contributes nothing to the fourth quarter, so its commercial impact remains unproven.
The company is also unprofitable, with a trailing-twelve-month net loss and negative operating cash flow. Cash stood near $41 million as of September 30, 2026, and the share count has risen as a result of prior equity issuance, creating potential dilution risk. Slowing demand, further reimbursement or competitive setbacks, or a broader rotation away from speculative small-cap health care names could all keep the shares far from a double-digit target.
Technical Levels and Market Structure
The shares trade well below both their 50-day and 200-day moving averages after the post-earnings decline, and the recent breakdown below roughly $3 leaves the 52-week low near $2.20 as a nearby support zone to monitor. On the upside, the prior $4 area and the 52-week high near $7.95 represent meaningful resistance levels; a sustained move toward $10 would require clearing both before any test of the central target becomes relevant. From what I see, these levels are worth monitoring closely.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of about 12 months, though individual firms may differ. Key items to watch include the fourth-quarter 2026 results and any formal 2027 guidance, the broader commercial launch of TriNav Advance, the interim PROTECT data expected in early 2027, and the January 2027 implementation of the new CMS reimbursement rates. Analyst target revisions — such as the recent Canaccord cut — are also worth tracking, as they signal changing views on the pace of the commercial ramp.
Leveraging Tickeron’s AI Daily Buy/Sell Signals
In my view, tools like this help keep an eye on volatile names without constant manual checks. Tickeron’s AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile small-cap name like TriSalus Life Sciences, such tools can help traders discover opportunities, keep an eye on positions, and spot shifting trends more efficiently than manual screening alone. I’m watching this closely for any signal shifts ahead of key catalysts.
Final Assessment
The $10 central target is derived from five analyst targets averaging $9.80, with a wide $4 to $14 range and uniform Buy ratings. Against a price near $2.85, reaching that level would require roughly 251% appreciation — a very large move that depends less on valuation than on a successful commercial re-acceleration. The FDA clearance of TriNav Advance and the 2027 CMS reimbursement increases offer genuine catalysts, but three consecutive guidance cuts, an unproven product launch, and persistent cash burn are substantial obstacles. Investors should watch 2027 guidance, TriNav Advance adoption, and clinical data before drawing conclusions, and no analyst target should be treated as a forecast of what the stock will actually do.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
TLSI's Indicator enters downward trend
The Aroon Indicator for TLSI entered a downward trend on November 10, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 165 similar instances where the Aroon Indicator formed such a pattern. In 139 of the 165 cases the stock moved lower. This puts the odds of a downward move at 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TLSI as a result. In 57 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 59%.
The Moving Average Convergence Divergence Histogram (MACD) for TLSI turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 61 similar instances when the indicator turned negative. In 32 of the 61 cases the stock turned lower in the days that followed. This puts the odds of success at 52%.
The 50-day moving average for TLSI moved below the 200-day moving average on November 03, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for TLSI's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +8.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLSI advanced for three days, in 136 of 212 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
TLSI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TLSI's P/B Ratio (30.552) is slightly higher than the industry average of (4.142). P/E Ratio (-2.444) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (5.459) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. TLSI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement